• eTheRNA
  • Follow our progress in developing products that have the potential to transform the future of cancer treatment

PCI Biotech and eTheRNA immunotherapies initiate research collaboration

Exploring synergies between PCI and TriMix technologies to further enhance the effect of novel oncologic therapies

Oslo (Norway) and Niel (Belgium), 8 December 2016 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and eTheRNA immunotherapies NV, a VUB spin-off company backed by strong life science investors to continue the development of mRNA-based immunotherapies, today announced that they are initiating a preclinical research collaboration.